{"id":"arq-197-plus-erlotinib","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Rash"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The combination of ARQ 197 and erlotinib targets the EGFR and c-MET pathways, which are involved in the growth and spread of cancer cells. This dual inhibition can potentially lead to a more effective treatment of certain types of cancer.","oneSentence":"ARQ 197 is a small molecule inhibitor of c-MET, and when combined with erlotinib, targets the EGFR and c-MET pathways.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:29:21.523Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Other cancers with EGFR and c-MET overexpression"}]},"trialDetails":[{"nctId":"NCT01244191","phase":"PHASE3","title":"Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer","status":"TERMINATED","sponsor":"Daiichi Sankyo","startDate":"2011-01-11","conditions":"Non Squamous, Non-small-cell Lung Cancer","enrollment":1048},{"nctId":"NCT01178411","phase":"PHASE1, PHASE2","title":"An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols","status":"COMPLETED","sponsor":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","startDate":"2010-08-31","conditions":"Advanced Solid Tumors","enrollment":60},{"nctId":"NCT01688973","phase":"PHASE2","title":"Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-08-20","conditions":"Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer","enrollment":55},{"nctId":"NCT01395758","phase":"PHASE2","title":"Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","startDate":"2011-07","conditions":"Metastatic Non-Small Cell Lung Cancer","enrollment":96},{"nctId":"NCT01069757","phase":"PHASE1","title":"A Study of ARQ 197 in Combination With Erlotinib","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2010-02","conditions":"Non-small-cell Lung Cancer","enrollment":16},{"nctId":"NCT01251796","phase":"PHASE1","title":"A Study of ARQ 197 in Combination With Erlotinib","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2010-12","conditions":"Advanced/Recurrent Non-small-cell Lung Cancer","enrollment":9},{"nctId":"NCT01377376","phase":"PHASE3","title":"A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib","status":"TERMINATED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2011-07","conditions":"Non-small-cell Lung Cancer","enrollment":""},{"nctId":"NCT01580735","phase":"PHASE2","title":"ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2012-05","conditions":"Non-small-cell Lung Cancer","enrollment":40},{"nctId":"NCT00777309","phase":"PHASE2","title":"A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","startDate":"2008-09","conditions":"Non Small Cell Lung Cancer","enrollment":167},{"nctId":"NCT00612703","phase":"PHASE1","title":"A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","startDate":"2008-02","conditions":"Cancer","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tivantinib"],"phase":"phase_2","status":"active","brandName":"ARQ 197 plus erlotinib","genericName":"ARQ 197 plus erlotinib","companyName":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","companyId":"arqule-inc-a-subsidiary-of-merck-sharp-dohme-llc-a-subsidiary-of-merck-co-inc-ra","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ARQ 197 is a small molecule inhibitor of c-MET, and when combined with erlotinib, targets the EGFR and c-MET pathways. Used for Non-small cell lung cancer, Other cancers with EGFR and c-MET overexpression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}